[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Case Report/Case Series
December 2013

Effects of Oral Propranolol on Circumscribed Choroidal HemangiomaA Pilot Study

Author Affiliations
  • 1Department of Ophthalmology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
  • 2Department of Cardiology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
  • 3Department of Clinical Research Promotion, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
JAMA Ophthalmol. 2013;131(12):1617-1622. doi:10.1001/jamaophthalmol.2013.5669
Abstract

Importance  Oral propranolol hydrochloride treatment has been proven effective for infantile hemangiomas. To our knowledge, this study is the first to report multiple cases in which oral propranolol therapy was used for patients with circumscribed choroidal hemangioma.

Observations  Five patients with circumscribed choroidal hemangioma were treated at Nagoya Medical Center, Nagoya, Japan, from 2011 to 2012. Oral propranolol hydrochloride was initiated at 10 mg 3 times a day and was increased monthly by 30 mg/d until the desired effects were observed. The mean (SD) height of the tumor (based on the B-mode at the end of the study) was 84.5% (13.6%) relative to the initial height. Similarly, the mean (SD) tumor area (based on indocyanine green angiography) was 94.2% (6.0%), the mean (SD) visual acuity was 0.04 (0.21) logMAR, and the mean (SD) Humphrey visual field mean deviation was −0.98 (1.1) dB. In 3 patients with macular edema, the mean (SD) foveal thickness (measured with optical coherence tomography) was 114.0% (13.9%).

Conclusions and Relevance  Although oral propranolol therapy may partially improve the condition of patients with circumscribed choroidal hemangioma, it does not seem to have a critical therapeutic effect, at least at blood concentrations lower than 50 to 100 ng/mL.

Trial Registration  umin.ac.jp/ctr Identifier: UMIN000006623

×